Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-08-13 Regulatory Filings
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated August 13, 2025, addressed to stock exchanges (BSE and NSE) regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is about informing the exchanges of upcoming investor conferences and meetings, explicitly stating that no unpublished price sensitive information will be discussed. There are no financial statements, detailed financial data, or report contents included. The document is brief (2134 characters) and serves as an announcement of a meeting schedule rather than a financial report or detailed investor presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-13 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a media release announcing that Senores Pharmaceuticals has acquired ANDAs from Teva Pharmaceuticals USA, Inc. It is addressed to stock exchanges (BSE and NSE) pursuant to SEBI Listing Regulations, indicating a regulatory disclosure. The content focuses on the acquisition transaction and funding through IPO proceeds, with no financial statements or detailed financial analysis included. The document is about a corporate event (acquisition) and is a formal announcement rather than a full report or detailed filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or M&A filings that require detailed merger documentation. Instead, it is best classified as a Capital/Financing Update (CAP) because it relates to acquisition funded by IPO proceeds and informs investors about a significant capital deployment event. The document length (5853 characters) supports it being a full announcement rather than a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2025-08-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is about notifying the schedule of investor conferences and meetings, explicitly stating that no unpublished price sensitive information will be discussed. There are no financial statements, no detailed financial data, no earnings or annual report content, and no voting or governance information. The document is short (2141 characters) and serves as an announcement of upcoming investor meetings rather than a report or detailed presentation. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-08-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 98% confidence The document is a detailed transcript of an earnings conference call for Q1FY26 of Senores Pharmaceuticals Limited. It includes management commentary, financial highlights, growth figures, segment performance, and outlook. The text explicitly mentions it is a transcript of the earnings call held on July 24, 2025, and contains detailed discussion of quarterly financial results, including revenue, EBITDA, PAT, and operational updates. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, contains substantive financial data and management discussion, and is not merely an announcement or a brief summary. Therefore, the correct classification is CT with high confidence.
2025-07-30 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) disclosing the completion of a USFDA inspection at a material subsidiary of the company. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to material event disclosures. The content is an announcement of an event (inspection completion and observations) rather than a financial report or detailed management discussion. The document length is short (1859 characters), and it does not contain financial data, audit information, or detailed report content. It is an official regulatory disclosure about a material event affecting the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing about the audio recordings of an Earnings Conference Call for the quarter ended June 30, 2025. It references compliance with SEBI regulations and states that the audio recording is available on the company's website. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the call recording. The document length is 2263 characters, which is relatively short and fits the pattern of an announcement rather than the full call transcript or financial report. Therefore, it should be classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call recording, not the call transcript itself or the earnings release.
2025-07-24 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.